Michael Horowitz — ASN Events

Michael Horowitz

University of Adelaide, Discipline of Medicine, SA, Australia

  • This delegate is presenting an abstract at this event.
  • Endocrinologist
Professor Michael Horowitz AO has led the Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health at the University of Adelaide since 2007. He is Director of the Endocrine and Metabolic Unit at the Royal Adelaide Hospital. His research activities focus on gastrointestinal motor, sensory, and hormonal function, particularly in relation to diabetes mellitus, appetite regulation and critical illness. He has co-authored 783 peer-reviewed papers and 42 book chapters - his h-index is 131. He holds a NHMRC L3 Investigator Grant (2020-2024). Professor Horowitz was awarded the degree of Doctor of Science by the University of Adelaide in 2021. In 2022 he was awarded the Camillo Golgi Prize by the European Association for the Study of Diabetes. In the 20023 King’s Birthday Honours, Michael was became an Officer of the Order of Australia for distinguished service to endocrinology, particularly diabetes, as a researcher, educator and clinician.
Presentations this author is a contributor to:

Hyperglycaemia potentiates GLP-1 induced slowing of gastric emptying (#91)

9:00 AM
Mark P Plummer
ADS Clinical Young Investigator Awards

Five weeks of resveratrol supplementation has no effect on GLP-1 secretion, gastric emptying, or glycemic control in type 2 diabetes (#375)

2:00 PM
Michelle J Bound
ADEA Poster Viewing One

Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males (#70)

4:00 PM
Tongzhi Wu
ADS Clinical Orals: Gut and Glycaemia

Effects of vildagliptin and/or a whey preload on postprandial glycaemia in patients with type 2 diabetes using metformin (#259)

2:00 PM
Tongzhi Wu
ADS Clinical Poster Prize Presentations

Relationships of ‘Early’ And ‘Late’ Glycaemic Responses With Gastric Emptying During An Oral Glucose Tolerance Test In Subjects With Normal Glucose Tolerance, Impaired Glucose Tolerance And Type 2 Diabetes (#285)

2:00 PM
Chinmay S Marathe
ADS Clinical Poster Viewing: Glycaemia/Monitoring

The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in health and type 2 diabetes: a randomised controlled trial.  (#71)

4:15 PM
Chinmay S Marathe
ADS Clinical Orals: Gut and Glycaemia

Effects of exenatide on the blood pressure and heart rate responses to intraduodenal glucose in type 2 diabetes (#168)

4:30 PM
Chinmay S Marathe
ADS Clinical Orals: Therapies for Type 2 Diabetes

A low-dose whey protein preload slows gastric emptying and improves post-prandial glycaemia in type 2 diabetes (#69)

3:45 PM
Linda E Mignone
ADS Clinical Orals: Gut and Glycaemia

Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in healthy older subjects and type 2 diabetes. (#92)

9:15 AM
Laurence G Trahair
ADS Clinical Young Investigator Awards

Effects of intragastric administration of leucine or isoleucine on gastric emptying of, and the blood glucose responses to, a mixed-nutrient drink, and on subsequent energy intake in healthy, normal-weight humans (#254)

2:00 PM
Sina S Ullrich
ADS Basic Poster Discussions - Mechanistic studies of insulin resistance

Personalised Glucose Therapy: Glucose Targets in Critically Ill Patients with Pre-Existing Poorly Controlled Type 2 Diabetes (#90)

8:45 AM
Palash Kar
ADS Clinical Young Investigator Awards